Pioneering Diagnostics

November is Clostridioides difficile awareness month.

C. difficile is one of the most challenging healthcare-associated infections (HAI), accounting for more than 60% of all cases of healthcare-associated diarrhea1. C. difficile is usually contracted in the healthcare setting and is connected to antibiotic treatment. C. difficile infection (CDI) incurs costly treatment, patient isolation and longer hospital stays.

Over 450 000 cases of CDI occur in the US annually, with over 80 000 first recurrences and approximately 29 000 deaths2. In Europe, over 123 000 cases were reported in 20163. Antibiotics cause a microbiota damage, with the potential establishment of a long lasting poor-species microbiota susceptible to pathogen invasion.

bioMérieux offers a comprehensive solution for all the steps of the CDI diagnostics and management.

Need more information?

Simply fill out the form below to talk to your local representative

By submitting this form, you agree to the processing of your personal data in accordance with our Privacy Statement.

 

Screening & Toxin detection

 

VIDAS® C. difficile panel: An automated offer

Rapid identification of C. difficile infection The VIDAS®C. difficile panel includes two complementary tests used as an aid in the diagnosis of C. difficile infection.

VIDAS® C. difficile GDH is a qualitative test that detects the C. difficile antigen, glutamate dehydrogenase (GDH), in stool specimens to screen patients suspected of having a C. difficile infection. It is used in conjunction with

VIDAS® C. difficile Toxin A & B as part of a two-step algorithm. Both tests are based on the ELFA (Enzyme-Linked Fluorescent Assay) technique

 

Culture

CHROMID® Range

For culture testing, bioMérieux’s CHROMID® C. difficile offers clear identification in just 24 hours 4,5, up to 30% more sensitive than conventional media4. Results are extremely easy to read, with black/dark grey colonies contrasting clearly on a pale agar.

 

 

Epidemiological assessment

 

EPISEQ® CS for clinical pathogens outbreak monitoring

Next Generation Sequencing software to determine the transmission pathway in case of C.diff outbreak. EPISEQ® CS includes a highly discriminant bacterial typing technics based on raw Whole Genome Sequencing data and delivers the list of resistance and virulence genes present on the bacterial genome.

EPISEQ® 16S for microbiome profiling studies

EPISEQ® 16S determines the microbial composition of stools samples based on the 16S rRNA gene. It helps to monitor the microbial flora from dysbiosis towards the recovery of a healthy microbiota in case CDI or to monitor to impact of antibiotics treatment of the stool's microbiota6
CDIs are an important HAI, and need to be monitored, as part of the Anti-Microbial Stewardship program of your institution. Discover our booklet on CDIs ”Clostridioides difficile infections, from Diagnosis to Outbreak Management”

 

References :

1 Antibiotic Resistance Threats in the United States, CDC 2013, https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.

2 Guh AY, Mu Y, Winston LG et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med 2020;382:1320–30. DOI:10.1056/NEJMoa1910215

3 Clostridioides difficile infections - Facts and surveillance, European Center for Diseases control website, https://www.ecdc.europa.eu/en/clostridium-difficile-infections/facts

4 Boseiwaqa LV, et. al. Comparison of CHROMID C. difficile agar and cycloserine-cefoxitin-fructose agar for the recovery of Clostridium difficile. Pathology. 2013 Aug;45(5):495-500. doi: 10.1097/PAT.0b013e3283632680.

5 Perry D. J. et al. Evaluation of a Chromogenic Culture Medium for isolation of Clostridium difficile within 24 hours. Journal of Clinical Microbiology– 2010; 48:3852-3858.

6 Thorpe CM, Kane AV, Chang J, Tai A, Vickers RJ, Snydman DR (2018) Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. PLoS ONE 13(8): e0199810

Copyright bioMérieux SA